Sirolimus trials
| | | | |
SIRIUS (2003)4 | 0.09 (0.05 to 0.16) | 0.24 (0.16 to 0.36) | 0.24 (0.15 to 0.39) | 0.38 (0.26 to 0.55) |
E-SIRIUS (2003)1 | 0.09 (0.04 to 0.22) | 0.14 (0.07 to 0.28) | 0.19 (0.09 to 0.43) | 0.35 (0.19 to 0.65) |
C-SIRIUS (2004)3 | 0.02 (0.001 to 0.40) | 0.04 (0.01 to 0.32) | 0.22 (0.05 to 1.03) | 0.22 (0.05 to 1.03) |
DIABETES (2005)30 | 0.15 (0.06 to 0.39) | 0.22 (0.10 to 0.47) | 0.24 (0.10 to 0.59) | 0.31 (0.15 to 0.66) |
RAVEL (2002)2 | 0.02 (0.001 to 0.26) | 0.02 (0.001 to 0.26) | 0.02 (0.001 to 0.29) | 0.20 (0.09 to 0.44) |
SES-SMART (2004)8 | 0.10 (0.04 to 0.23) | 0.18 (0.10 to 0.34) | 0.33 (0.16 to 0.70) | 0.30 (0.16 to 0.57) |
Combined IRR | 0.10 (0.07 to 0.14) | 0.20 (0.15 to 0.26) | 0.24 (0.17 to 0.33) | 0.33 (0.25 to 0.42) |
Heterogeneity* | 0.0%, p = 0.63 | 33.6%, p = 0.18 | 0.0%, p = 0.51 | 0.0%, p = 0.78 |
Paclitaxel trials
| | | | |
TAXUS I (2003)5 | 0.14 (0.01 to 2.67) | NA | 0.14 (0.01 to 2.77) | 0.25 (0.03 to 2.24) |
TAXUS II (2003)6, 32, 33 | 0.33 (0.19 to 0.55) | 0.18 (0.09 to 0.36) | 0.27 (0.13 to 0.53) | 0.58 (0.38 to 0.86) |
TAXUS IV (2004)7, 29 | 0.23 (0.13 to 0.39) | 0.30 (0.19 to 0.47) | 0.32 (0.22 to 0.46) | 0.56 (0.41 to 0.78) |
TAXUS VI (2005)31 | 0.28 (0.17 to 0.46) | 0.35 (0.22 to 0.54) | 0.42 (0.25 to 0.72) | 0.73 (0.48 to 1.12) |
Combined IRR | 0.27 (0.20 to 0.37) | 0.29 (0.22 to 0.39) | 0.33 (0.25 to 0.44) | 0.60 (0.48 to 0.75) |
Heterogeneity* | 0.0%, p = 0.77 | 16.3%, p = 0.30 | 0.0%, p = 0.67 | 0.0%, p = 0.65 |
RIRR (sirolimus v paclitaxel) | 0.35 (0.21 to 0.57) p<0.001 | 0.68 (0.45 to 1.01) p = 0.057 | 0.71 (0.46 to 1.09) p = 0.120 | 0.54 (0.39 to 0.76) p<0.001 |